NASDAQ$EVLO

Evelo Biosciences Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$12.60

Previous: -$9.00-40.0%
Capital Expenditures

-$1.96M

Previous: -$912K-115.1%
Free Cash Flow

-$70.8M

Previous: -$55M-28.8%
Net Income

-$33.7M

Previous: -$20.9M-61.2%
Operating Income

-$32.7M

Previous: -$20.2M-62.1%
Gross Profit

$0.00

Previous: $0.00
Cash & Equivalents

$95.9M

Previous: $81.6M+17.6%
Total Assets

$116M

Previous: $105M+11.1%
R&D Expense

$22.6M

Previous: $14.9M+51.6%

Revenue & EPS history

Evelo · Revenue · Quarterly

$0

Q3 2021

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+1.3%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-9.7%

Avg return

30 days after

54%

13 / 24 earnings

Positive

+32.3%

Q2 2023

Best reaction

-20.3%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2023+0.0%+0.0%-9.8%
Q3 2023-7.6%+4.5%+3.8%
Q2 2023+32.3%-30.5%-41.0%
Q1 2023+2.9%+10.2%-28.8%
Q4 2022-17.8%-27.0%-46.9%
Q3 2022+3.3%-3.3%-8.5%
Q2 2022-7.1%-10.5%-25.4%
Q1 2022-20.3%-14.5%-2.4%
Q4 2021+29.4%+13.5%-26.3%
Q3 2021+10.2%+27.0%+6.0%
Q2 2021-0.9%+5.0%+20.7%
Q1 2021+8.8%-14.4%+11.0%
Q4 2020+14.5%+21.2%+1.6%
Q3 2020-12.9%-5.9%+14.0%
Q2 2020-1.6%-0.5%+15.2%
Q1 2020-5.7%-14.0%-20.9%
Q4 2019+1.8%+12.2%-28.4%
Q3 2019-3.3%-6.1%-35.9%
Q2 2019+3.9%-2.2%+7.0%
Q1 2019+0.8%-1.5%-11.8%
Q4 2018+1.3%+3.0%-6.9%
Q3 2018+0.2%+3.4%+3.7%
Q2 2018-3.4%-5.9%+2.6%
Q1 2018+1.8%+2.2%-24.8%
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro